Posts by DCprime

DCPrime and apceth Biopharma GmbH announce manufacturing partnership

Leiden, The Netherlands, and Munich, Germany – DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an established contract manufacturing organization in the field of gene and cell therapy, report today that they have entered into a strategic manufacturing agreement. The collaboration involves clinical batch production and

DCPrime obtains patent protection for DCOne® platform

DCPrime obtains broad patent protection in the EU for proprietary DCOne® platform. DCPrime, a clinical stage cancer immunotherapy company, has been granted a European patent on its DCOne® platform. The patent covers its proprietary cell line DCOne®, the accompanying methods for obtaining mature dendritic cells, and the mature dendritic cells which are obtainable by this method,

DCPrime and VUmc awarded €6 million Euro Horizon2020 grant

DCPrime and VUmc awarded Horizon2020 grant to support the development of a dendritic-cell vaccine therapy for Acute Myeloid Leukemia. DCPrime, a Dutch cancer immunotherapy company, and the Department of Hematology of the VU medical center in Amsterdam, announce that, together with a strong international consortium of academic and company partners, they have been awarded a 6

DCPrime and Dana Farber Cancer Center start collaboration on cancer immunotherapy treatment of Multiple Myeloma

Leiden, The Netherlands – Dutch clinical stage company DCPrime BV, dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that it has started a collaboration on the potential application of its lead product DCP-001 in Multiple Myeloma patients with Prof. Dr. David Avigan, Beth Israel Deaconess Medical Center, Dana

DCPrime granted €1.2 million government loan for development of its lead product in novel indications

Leiden, The Netherlands – DCPrime, a clinical stage company dedicated to developing cancer vaccines based on its proprietary dendritic cell (DC) technology platform DCOne®, today announced that the Dutch Ministry of Economic Affairs, via its agency RVO (Rijksdienst voor Ondernemend Nederland), will support DCPrime B.V. for extending the applications of its lead product DCP-001 to other hematological

Strategic Investment by Van Herk Group in Cancer Vaccine Company DCPrime

Rotterdam, Leiden – Van Herk Royalty, part of the Van Herk Groep, announced today a strategic investment of an undisclosed sum in Dutch cancer vaccine company DCPrime. The financing provides DCPrime with funding for the further development of its technology platform, and is in line with the long-term investment strategy of the Van Herk Group.